Cardiac Science Announces Third Quarter Results.

IRVINE, Calif.--(BW HealthWire)--Nov. 10, 1998--Cardiac Science Inc. (OTC:DFIB), the developer of the Powerheart(R) fully automatic hospital bedside defibrillator-monitor and proprietary AECD(R) cardiac arrest detection and defibrillation software(tm), reported revenues of $318,940 and a net loss of $802,841, or 14 cents a share, for the third quarter ended Sept. 30.

R&D expenses relating to the development of the commercial version of the Powerheart(R) defibrillator-monitor totaled $437,889 or 55 percent of quarter's total loss. Revenue for the quarter was attributed to sales of the company's ambulatory Holter ECG product line sold via its Diagnostic Monitoring subsidiary, with export sales accounting for 85 percent of the company's revenue.

Third quarter results compared with revenues of $380,050 and a net loss of $367,080, or 10 cents a share, for the same period in 1997. For the nine-month period ending Sept. 30 the company reported revenues of $1,121,296 and a net loss of $2,597,847 or 49 cents a share, compared with revenues of $789,048 and a net loss of $806,632 or 23 cents a share, for the same period in 1997.

Cardiac Science designs and markets proprietary non-invasive resuscitation devices that increase the survival rates of cardiac arrest victims. Cardiac Science's products are the only external devices cleared by the FDA that continuously monitor in-hospital patients at risk of sudden cardiac arrest, instantly detect life threatening heart rhythms and when appropriate, deliver defibrillation shocks within seconds without human intervention to jump-start the heart. Response-time to first defibrillation is critical. For each minute that passes after the onset of a life-threatening tachyarrhythmia, the chance of survival declines 10-15 percent. Early rhythm assessment and immediate defibrillation means significantly increased survival rates, reduced damage to heart and other vital organs, including the brain, which may lessen debilitation and quicken recovery periods.

In August 1998, the company received FDA-clearance to integrate its proprietary AECD(R) Tachyarrhythmia Detection Software(tm) into bedside monitor-defibrillator platforms. Integration of Cardiac Science's software technology into external defibrillators and patient monitors widely used in hospitals has the potential to save thousands of lives annually. The company is pursuing strategic partnerships to license its cardiac arrest detection and defibrillation software technology.

Cardiac Science also manufactures PC-based Holter ECG systems and Holter recorders and distributes these products in the United States and in over 40 countries, through its subsidiary, Diagnostic Monitoring. For more information, visit the company's Internet sites at www.cardiacscience.com and www.diagnosticmonitoring.com.

This news release contains forward-looking statements, including but not limited to those regarding Cardiac Science's ability to improve patient-care, increase survival rates for in-hospital cardiac arrest victims, and reduce patient care costs. Actual results could vary materially from the description contained herein due to many factors, including hospital operations, market and clinical users acceptance of new and existing products, impact of competitive products and pricing, changing market conditions, and risks detailed in the company's Form 10-KSB for the year ending Dec. 31, 1997 and other documents filed with the Securities and Exchange Commission. The company does not undertake any obligation to update the information contained herein, which speaks only as of this date. The Powerheart(R), AECD(R) and AECD Tachyarrhythmia Detection Software(tm) are trademarks of Cardiac Science Inc.